With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.93319-65-4,Pyridazin-3-ylmethanamine,as a common compound, the synthetic route is as follows.
93319-65-4, General procedure: A solution of 1-isopropyl-6-methyl-4-oxo-5-(3-trifluoromethyl-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid (preparation 3, 65 mg, 0.192 mmol), TBTU (75 mg, 0.232 mmol), N-methylmorpholine (42 muL, 0.383 mmol) in DMF (1 mL) is stirred for 15 min at room temperature. C-(5-Methyl-[1,3,4]oxadiazol-2-yl)-methylamine (24 mg, 0.211 mmol) is added and the reaction mixture is stirred for 18 h at room temperature. The reaction mixture is purified by preparative reversed-phase HPLC (Sunfire, gradient of acetonitrile in water, 0.1% TFA, 60 C.). The following examples are prepared as described for Example 3.1, substituting preparation 3 with preparation 4, substituting N-methylmorpholine with triethylamine and employing the appropriate amines, respectively.
93319-65-4 Pyridazin-3-ylmethanamine 22639518, apyridazine compound, is more and more widely used in various fields.
Reference£º
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; OOST, Thorsten; FIEGEN, Dennis; GNAMM, Christian; HANDSCHUH, Sandra; PETERS, Stefan; ROTH, Gerald Juergen; US2014/57920; (2014); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem